Patheon to 'reposition' Swindon plant
Canadian drug discovery services company Patheon has adopted a 'repositioning plan' at its facility in Swindon, UK, designed to reduce operating losses at the site in 2005 and lead to profitability in fiscal 2006.
Canadian drug discovery services company Patheon has adopted a 'repositioning plan' at its facility in Swindon, UK, designed to reduce operating losses at the site in 2005 and lead to profitability in fiscal 2006.
The repositioning plan includes both a cut in the workforce and a reorganisation of production processes. The site will focus on sterile pharmaceutical manufacturing, including both aseptically filled and terminally sterilised liquids and cephalosporin antibiotic products.
There will be a reduction of around 60 positions in the site's commercial operations staff, representing about 11% of the site's total workforce. Most, if not all, of the proposed reduction is expected to be achieved on a voluntary basis and should be completed by the end of October.
'Swindon is an excellent sterile manufacturing site and we are confident that it can continue to be a strategic asset in Patheon's global network,' said Robert Tedford, ceo of Patheon.